Company Overview of MicroBiome Therapeutics, LLC
MicroBiome Therapeutics, LLC, a biotechnology company, develops medical food and pharmaceutical products. The company focuses on developing evidence-based microbiome modulators, which are designed to alter bacteria populations and their environment in the gastrointestinal tract in specific ways to treat and prevent serious health conditions. Its product includes NM504, which contains a combination of prebiotic and other naturally occurring ingredients formulated to help diabetic individuals achieve healthy blood glucose levels and manage their body weight. MicroBiome Therapeutics, LLC was formerly known as NuMe Health LLC. The company was founded in 2009 and is based in Broomfield, Colorado.
11001 W 120th Avenue
Broomfield, CO 80021
Founded in 2009
Key Executives for MicroBiome Therapeutics, LLC
Chief Scientific Officer and Vice President of Research
Compensation as of Fiscal Year 2014.
MicroBiome Therapeutics, LLC Key Developments
MicroBiome Therapeutics(TM) LLC Presents Positive Results from a Clinical Trial of Microbiome Modulator NM504 in Prediabetes and Type 2 Diabetes at ICE/ENDO 2014
Jun 23 14
MicroBiome Therapeutics(TM) LLC presented positive results from a clinical trial of microbiome modulator NM504 in prediabetes and type 2 diabetes at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society. This is the first double-blind, randomized, placebo-controlled trial to demonstrate that a microbiome modulator can improve blood glucose control and other metabolic parameters in patients with diabetes. NM504 is designed to shift the gastrointestinal (GI) microbiome to correct the GI dysbiosis, or microbial imbalances, that are associated with type 2 diabetes and prediabetes. The trial was designed to assess whether NM504's modulation of the GI microbiome would result in better glycemic control in these patients. The results confirmed that NM504 significantly improved blood glucose control, lowering blood glucose and increasing levels of insulin in both patient populations. In addition, NM504 decreased cholesterol levels and markers of chronic inflammation in the treated patients. NM504 was well tolerated in the trial with no drug-related adverse events, and patient compliance was excellent. Earlier this month the US Centers for Disease Control and Prevention issued its 2014 National Diabetes Statistics Report indicating the diabetes epidemic continues to grow at an alarming rate. Currently, some 29 million people in the US have diabetes and an additional 86 million American adults nearly one in three has prediabetes. An estimated 15 to 30% of people with prediabetes will go on to develop the full-fledged disorder within five years.
MicroBiome Therapeutics(TM) LLC Reports Positive Top-Line Results from Clinical Trial of Microbiome Modulator NM504 in Type 2 Diabetes
Feb 18 14
MicroBiome Therapeutics(TM) LLC announced results from the company's clinical trial of microbiome modulator NM504 in development for type 2 diabetes and prediabetes. NM504 is designed to improve glucose tolerance and other metabolic parameters in patients with diabetes by shifting the gastrointestinal (GI) microbiome. Studies have shown that type 2 diabetics typically have GI dysbiosis, or microbial imbalances, that may contribute to the metabolic dysfunction associated with the condition. The double-blind, randomized, placebo-controlled trial assessed whether NM504 administered for four weeks could improve the glucose tolerance of subjects with prediabetes and untreated type 2 diabetes by modulating the GI microbiome. The study enrolled 42 subjects. Top-line results show that twice-daily oral administration of NM504 reduced postprandial serum glucose levels and increased insulin sensitivity in these subjects. The results were statistically significant as measured by an oral glucose tolerance test. NM504 also decreased markers of chronic inflammation and blood lipids in treated subjects, and it decreased appetite as determined by a validated physician-administered scale. NM504 was well tolerated and patient compliance was excellent.
NuMe Health LLC Hires Steve Orndorff as its Chief Executive Officer
Aug 7 13
NuMe Health LLC announced that the company has hired Steve Orndorff, Ph.D., as chief executive officer. Prior to joining MBT, Dr. Orndorff was CEO of Ariel Pharmaceuticals. Previously he was CEO of Accera, which commercialized a prescription-only pharmacogenomic medical food for Alzheimer's patients and Univera Pharmaceuticals, a developer of novel anti-inflammatory drugs derived from natural products. Earlier in his career, Dr. Orndorff held positions of increasing responsibility for R&D and manufacturing at PharmaLogix, ZeaGen and Monsanto's NutraSweet subsidiary.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 30, 2013